This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

AstraZeneca's Scrappy Defenders Against Pfizer's Billions

NEW YORK (TheStreet) -- Chuka Umunna, the Labour MP from Streatham, U.K., and the Shadow Business Secretary, is an angry man.

What's got him riled is American pharma giant Pfizer's (PFE - Get Report) transatlantic bid to acquire British drugmaker AstraZeneca (AZN - Get Report)  in a mammoth $106 billion deal. Umunna has attacked Pfizer's track record in acquisitions as "intellectual asset-stripping" exercises.

Mega-mergers and acquisitions are always saddled with controversy from the day matters become public, and Pfizer's bid to press ahead with the deal despite twice being turned down by its target has set the business world abuzz.

Playing out side-by-side is a political battle between the Conservative-led David Cameron government, which is batting for the deal, and the Labour Party, which sees the loss of U.K. jobs due to the acquisition as a rallying call for action.

The Liberal Democrats, as has increasingly become their lot, are sandwiched somewhere in between, their hearts probably with Labour but mindful of the fact that their own Vince Cable is in the hot seat as the Business Secretary.

Speaking of being sandwiched: Pfizer did its P.R. folks no favors when, in 2011, in a much-criticized move, it shut down its leading R&D center in Sandwich, in the U.K. county of Kent. The company employed 2,400 people at the site and a thriving local economy had mushroomed around the facility.

Tax experts point to another motivation for Pfizer to be looking toward the island nation. If the merger were to go through, Pfizer could make Britain its reporting location for tax purposes, saving a neat $1 billion in taxes.

This move to navigate away from U.S. taxes has also upset a few lawmakers on Capitol Hill. Proposals under consideration in the Senate as well as in Obama's 2015 budget would ban such practices by U.S. companies. No wonder Pfizer wants this deal to go through A.S.A.P.

Pfizer's version of its pursuit of AstraZeneca reads very differently from this talk, though. The company line is that the merger would create the largest pharma company in the world, and it would have greater and faster access to new markets, as well as a global research base.

Aware that such pronouncements are standard fare in such deals, Pfizer has indicated a willingness to protect jobs at AstraZeneca. The trouble is, the way private companies work, it is next to impossible to guarantee such a thing. Umunna, as reported by the more provocative sections of the British media, called these assurances "not worth the paper they are written on."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
AZN $65.01 -0.61%
PFE $33.49 0.36%
AAPL $125.68 -0.60%
FB $87.58 0.34%
GOOG $522.43 -0.19%

Markets

DOW 17,671.29 -58.82 -0.33%
S&P 500 2,070.26 -6.52 -0.31%
NASDAQ 4,996.0390 -13.1750 -0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs